Finding an object in mushrooms may change the life of Parkinson’s patients …
A preliminary study conducted by the University of California in San Francisco revealed surprising conclusions for patients with Parkinson’s patients.
Researchers have noticed significant progress even in patients’ mood, mental abilities and operating symptoms, which lasted several weeks after the material was out
Celoceipine has previously shown the ability to treat depression and tension, which prompted to explore whether it is beneficial for Parkinson’s disease at the University of California in San Francisco, which is a group that is repeatedly affected by severe mood disorders, and often responds to traditional antibiotics and other drugs.
Researchers found that the treatment of cellocephine did not expose participants to severe side effects or to increase their Parkinson’s symptoms, and they also reported moral improvements in mood, cognitive activity and motor control. These benefits lasted for several weeks after cells left their body.
It is noteworthy that this is the first study of drug drugs (illusion) in patients with neurological degeneration.
Dr. Ellen Bradley, the main writer of the study, has violated all expectations, especially Parkinson’s patients’ moods affect the quality of their lives more than the symptoms of operating systems, and are related to rapid decline in their health.
The study participated in the study of 12 patients who received two dose cellocephine with intensive psychological therapies.
Neurological diseases
To test the integrity of the cellocephin for these patients, the researchers have seven men and five females, followed by a mild of 10 mg, followed by 25 mg. Patients before and after Celeocin completed psychological therapy sessions – eight sessions in total – and they were evaluated for changes in mood, concept and motor functioning.
Although there are some simple side effects, such as anxiety and nausea, they are not dangerous. Most importantly, there was improvement after three months of experience.
Researchers believe that improvement may be due to the positive effect of celloosebin in the mood, which may be reflected in motor function, or its ability to reduce infections and stimulate the development of brain cells.
A major study is currently underway with the contribution of 100 patients to deeply discuss these hypotheses.
Dr. Joshua Wally, the director of the research program, confirms that these results are opening new borders in treating brain diseases, where we will find an object for the first time, not only to reduce symptoms, but also help the brain to adjust itself. Scitechdail
